- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Molnupiravir
Population: General population
Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- General population
- Children (1-11 years)
- Adolescents (12-17 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Hospital
- Non-hospital health centre
- Vaccination centre
- Monkeypox virus
- Blood sample
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- General population
- Non-hospital health centre
- Vaccination centre
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Non-hospital health centre
- Vaccination centre
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Immunoadsorption